In Lancet Oncology this week, an international team of researchers presents findings from a study of the utility of EGFR expression as a predictor of survival in non-small-cell lung cancer patients treated with first-line chemotherapy and cetuximab.
This Week in Lancet Oncology
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.